Status:
COMPLETED
Eliquis Regulatory Post Marketing Surveillance
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
NonValvular Atrial Fibrillation
Eligibility:
All Genders
19+ years
Brief Summary
The primary objective of this study is to examine the safety profile of Eliquis in Korean nonvalvular atrial fibrillation patients.
Eligibility Criteria
Inclusion
- For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
- Patients ≥19 years of age
- Adult patients who are diagnosed with nonvalvular atrial fibrillation and are initiating Eliquis anticoagulation therapy for risk reduction of stroke and systemic embolism
- Patients with evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study
Exclusion
- Receiving Eliquis treatment for an indication that is not approved in Korea
- Contraindicated for the use of Eliquis as described in the Korean label
Key Trial Info
Start Date :
July 10 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 29 2017
Estimated Enrollment :
3335 Patients enrolled
Trial Details
Trial ID
NCT01885598
Start Date
July 10 2013
End Date
September 29 2017
Last Update
October 31 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Seoul, South Korea, 110-756